Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 11/20 | 0.51 |
| ▸ | MAPK13 | O15264 | 10/20 | 0.48 |
| ▸ | MAPK12 | P53778 | 10/20 | 0.48 |
| ▸ | MAPK11 | Q15759 | 10/20 | 0.48 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.47 |
| ▸ | IDH1 | O75874 | 4/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7665192 | 1.00 | MAPK14 (0.51) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL7590696 | 0.90 | MAPK14 (0.52) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL7590690 | 0.90 | MAPK14 (0.52) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL7668093 | 0.89 | GABRA2 (0.56) | MAPK14GABRA2GABRB2IDH1LCK | |
| SCHEMBL7566543 | 0.86 | GABRA2 (0.48) | MAPK9GABRA2GABRB2 | |
| SCHEMBL7661360 | 0.83 | GABRA2 (0.45) | MAPK9GABRA2GABRB2 | |
| SCHEMBL7528721 | 0.82 | MAPK14 (0.54) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL7664658 | 0.82 | MAPK9 (0.61) | MAPK9GABRA2GABRB2 | |
| SCHEMBL7671470 | 0.82 | MAPK14 (0.55) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL7665100 | 0.81 | GABRA2 (0.45) | MAPK9GABRA2GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6492516-B1 | PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF WHICH EXHIBIT UTILITY FOR THE TREATMENT OF CYTOKINE MEDIATED DISEASES SUCH AS ARTHRITIS. | MERCK & CO., INC. | 2002-12-10 | — | — | US | disclosed |